Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Theodore Ford

Anesthesiology Bend, OR Medical Doctor

NPI 1205940830 CMS profile 145875

2542 Ne Courtney Dr Ste 200G, Bend, OR 97701

Open in the dashboard

General payments

$816

38 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Theodore Ford of Bend, OR is reported in the CMS Open Payments database as having received $816 across 38 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $17 1
2021 General $179 11
2020 General $226 10
2019 General $394 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Theodore Ford
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to Theodore Ford were reported at $0. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year Theodore Ford Anesthesiology median Middle half National median
2019 $394 $72 $23–$151 $163
2020 $226 $36 $17–$120 $114
2021 $179 $49 $21–$135 $132
2022 $0 $52 $22–$144 $149
2023 $17 $53 $23–$143 $160
2024 $0 $55 $25–$150 $164
2025 $0 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Abbott Laboratories $207 5 payments
  2. Amgen Inc. $125 1 payment
  3. Arbor Pharmaceuticals, Inc. $113 8 payments
  4. Pfizer Inc. $97 7 payments
  5. Biodelivery Sciences International, Inc. $77 5 payments
  6. SI-BONE, Inc. $47 3 payments
  7. Allergan Inc. $44 3 payments
  8. Bioventus LLC $32 2 payments
  9. Merz North America, Inc. $31 1 payment
  10. AbbVie, Inc. $17 1 payment
  11. Other $26 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $728 37 payments
  2. Education $89 1 payment
Products named General payments · program years 2019–2023
  1. EVENITY $125 1 payment
  2. Octrode SCS Leads $104 2 payments
  3. Proclaim Family of SCS IPGs $74 1 payment
  4. EMBEDA $70 5 payments
  5. LYRICA $70 5 payments
  6. BELBUCA $65 4 payments
  7. IFUSE IMPLANT $47 3 payments
  8. Horizant $44 3 payments
  9. BOTOX $44 3 payments
  10. FLECTOR PATCH $42 3 payments
  11. Other $291 20 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

2,369

Median for Interventional Pain Management: 1,220

Drug cost

$120,297

Median for Interventional Pain Management: $39,344

Branded share of claims

31.9%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 162 $23,988
Belbuca Buprenorphine Hcl Brand 21 $18,649
Oxycontin Oxycodone Hcl Brand 26 $14,465
Zubsolv Buprenorphine Hcl/Naloxone Hcl Brand 25 $14,350
Buprenorphine Generic 37 $10,263
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 372 $7,651
Movantik Naloxegol Oxalate Brand 12 $7,015
Buprenorphine Hcl Generic 237 $6,685
Tramadol Hcl Generic 324 $3,328
Gabapentin Generic 250 $2,770

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$34,422

Medicare's payments for the services billed

Medicare patients

64

Average age 69

Services billed

664

38 women, 26 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 58%
Depression 34%
Ischemic heart disease 22%
COPD 22%
Osteoporosis 19%
Diabetes 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

38 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Anesthesiology in Oregon

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record